SAN DIEGO--(BUSINESS WIRE)--MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com), the biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that Dr. Christopher Marsh joined the Company’s Scientific Advisory Board and was named MicroIslet’s lead transplant consultant, and that Dr. Ronald Goldblum has been retained as the Company’s lead clinical development consultant.